Shield Therapeutics extends cash runway into 2021 after significant China deal

Proactive Research analyst Emma Ulker discusses Shield Therapeutics PLC's (LON:STX) 2019 business update and subsequent licence agreement for Feraccru/Accrufer with the integrated specialty pharma company Beijing Aosaikang Pharmaceutical Co Ltd (ASK Pharm) which covers China, Hong Kong, Macau and Taiwan.

Ulker adds that a key highlight of 2019 included presentation of positive data from STX’s AEGIS head-to-head study of Feraccru vs the leading IV iron, Ferinject.

SHIELD THERAPEUTICS,emma ulker,